StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) stock

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.78−0.08 (-4.30%)

Close on Nov 17, 2026Market cap $58.25MP/E –Yield –

Insight Molecular Diagnostics total assets

Total assets on the balance sheet at the end of each period.

Insight Molecular Diagnostics's total assets was $29.44M at Jun 30, 2026. For fiscal 2025 it was $25.76M, down 26.6% from the year before. Over ten years it grew 7.3% a year on average. The highest annual figure on record is $159.56M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$25.76M-26.6%
FY2024Dec 31, 2024$35.08M-53.2%
FY2023Dec 31, 2023$74.89M-25.2%
FY2022Dec 31, 2022$100.09M-37.3%
FY2021Dec 31, 2021$159.56M+187.9%
FY2020Dec 31, 2020$55.42M+39.0%
FY2019Dec 31, 2019$39.86M+318.8%
FY2018Dec 31, 2018$9.52M-6.8%
FY2017Dec 31, 2017$10.22M-29.3%
FY2016Dec 31, 2016$14.45M+13.5%
FY2015Dec 31, 2015$12.73M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$29.44M-41.7%
Q1 FY2026Mar 31, 2026$40.43M-33.0%
Q4 FY2025Dec 31, 2025$25.76M-26.6%
Q3 FY2025Sep 30, 2025$43.94M-37.4%
Q2 FY2025Jun 30, 2025$50.52M-32.4%
Q1 FY2025Mar 31, 2025$60.36M-15.0%
Q4 FY2024Dec 31, 2024$35.08M-53.2%
Q3 FY2024Sep 30, 2024$70.22M-13.9%
Q2 FY2024Jun 30, 2024$74.72M-14.6%
Q1 FY2024Mar 31, 2024$70.97M-14.3%
Q4 FY2023Dec 31, 2023$74.89M-25.2%
Q3 FY2023Sep 30, 2023$81.59M-48.1%
Q2 FY2023Jun 30, 2023$87.54M-48.8%
Q1 FY2023Mar 31, 2023$82.80M-43.4%
Q4 FY2022Dec 31, 2022$100.09M-37.3%
Q3 FY2022Sep 30, 2022$157.34M-6.5%
Q2 FY2022Jun 30, 2022$171.05M-3.6%
Q1 FY2022Mar 31, 2022$146.27M+13.1%
Q4 FY2021Dec 31, 2021$159.56M+187.9%
Q3 FY2021Sep 30, 2021$168.34M+191.4%
Q2 FY2021Jun 30, 2021$177.38M+179.5%
Q1 FY2021Mar 31, 2021$129.31M+117.3%
Q4 FY2020Dec 31, 2020$55.42M+39.0%
Q3 FY2020Sep 30, 2020$57.78M+76.3%
Q2 FY2020Jun 30, 2020$63.46M+68.5%
Q1 FY2020Mar 31, 2020$59.50M+42.8%
Q4 FY2019Dec 31, 2019$39.86M+318.8%
Q3 FY2019Sep 30, 2019$32.77M+153.9%
Q2 FY2019Jun 30, 2019$37.67M+208.8%
Q1 FY2019Mar 31, 2019$41.68M+167.5%
Q4 FY2018Dec 31, 2018$9.52M-6.8%
Q3 FY2018Sep 30, 2018$12.91M-9.4%
Q2 FY2018Jun 30, 2018$12.20M+0.5%
Q1 FY2018Mar 31, 2018$15.58M+2.7%
Q4 FY2017Dec 31, 2017$10.22M-29.3%
Q3 FY2017Sep 30, 2017$14.25M-15.5%
Q2 FY2017Jun 30, 2017$12.14M–
Q1 FY2017Mar 31, 2017$15.17M–
Q4 FY2016Dec 31, 2016$14.45M–
Q3 FY2016Sep 30, 2016$16.86M–

More Insight Molecular Diagnostics figures

See a number that looks wrong?